Picture of Zydus Lifesciences logo

ZYDUSLIFE — Zydus Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Zydus Life quarterly profit slumps as costs weigh

India's Zydus Life quarterly profit slumps as costs weigh

- Indian drugmaker Zydus Lifesciences' ZYDU.NS first-quarter profit dropped by nearly a third, the company reported on Tuesday, as soaring costs offset strong sales in its key markets.

The company's consolidated net profit fell to 9.40 billion rupees ($98.5 million) for the quarter ended June 30, compared with 14.67 billion rupees a year ago.

Here are some more details:

  • Most Indian generic drugmakers, including Zydus Life, derive a significant portion of their revenue from the U.S. market but have been grappling with weak pricing due to intense competition.

  • Overall revenue jumped 22% to 80.17 billion rupees, but expenses rose at a faster pace of 41.4%, dragged by an over 32% jump in R&D costs and a 47.5% jump in other operating expenses.

  • However, the company's sales stayed strong with those in India jumping 19.5% to 18.16 billion rupees and those in its consumer wellness business, which owns brands such as Glucon D, surging 67.2% to 14.29 billion rupees.

  • North America sales, however, dropped 2.6% to 30.98 billion rupees.

  • Larger rivals Dr Reddy's REDY.NS and Cipla CIPL.NS posted subdued U.S. sales during the quarter.

($1 = 95.4300 Indian rupees)


(Reporting by Kashish Tandon in Bengaluru; Editing by Rashmi Aich and Harikrishnan Nair)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

Recent news on Zydus Lifesciences

See all news